President Donald Trump talks a lot. He talks to the press a lot. He talks to people on the phone a lot. He talks to visitors to the Oval Office a lot. And he talks to the public a lot, often through ...

Keep tabs on Texas politics and policy with our morning newsletter. The Texas Tribune Independent news. Trusted by Texans. About The Texas Tribune | Staff | Contact | Send a Confidential Tip | Ethics ...

Luciano Costa waited three years to see how patients with an aggressive bone-marrow cancer would fare on an experimental immunotherapy treatment. Reviewing the results gave him goose bumps. “Holy shit ...

Think fast delivery has reached absurd levels in the U.S.? Give a thought to India, where the government has asked all quick-commerce platforms to drop a "10-minute delivery" promise. According to BBC ...

Layoffs, declining occupancy, and weaker revenue have pushed several locations of the century-old hotel brand to close across the U.S. A well-known hotel chain is facing multiple closures of its U.S.

A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising results in a first in-human phase 1/2 trial. The TACTOPS trial, which ...

We’ve held off on discussing AI as long as we could, but we’re only human. It was the topic of 2025 (not only in retail), and its impact on the industry’s ecosystem looks set to expand even further in ...

An American rock band is getting ready to go out on tour soon. However, one of their members will notably be missing. The PRP reports how Clint Lowery — the guitarist for Atlanta, Georgia-based outfit ...

It looks like Elon Musk made a whole lot of 2025 promises that he couldn't keep. Credit: BRENDAN SMIALOWSKI/AFP via Getty Images By now, everyone knows that Elon Musk is very much an optimist when it ...

President Trump’s first year back in office saw a whirlwind of executive actions, the passage of a major reconciliation bill and the rapid remaking of the federal government. Trump campaigned in 2024 ...

Wells Fargo initiated coverage of Arcellx (ACLX) with an overweight rating saying that its experimental CAR-T therapy for multiple myeloma, anito-cel, is a "future pillar" in management of the blood ...